DYNC2H1 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the DYNC2H1 gene in the context of human non-small cell lung carcinoma. This heterogeneous pool of NCI-H1299 cells carries a loss-of-function modification in DYNC2H1, enabling researchers to study the functional consequences of dynein-2 heavy chain deficiency in a lung adenocarcinoma background. The polyclonal format provides a population-level knockout model without single-cell cloning, preserving the genetic diversity of the parental cell line while eliminating DYNC2H1 expression. This product is intended for advanced applications in cell biology, signal transduction, and cancer research, offering a versatile tool for investigating cilia-dependent pathways and their roles in tumorigenesis.
The host cell line, NCI-H1299, is a widely used human lung adenocarcinoma epithelial model derived from lymph node metastasis of a non-small cell lung carcinoma. It features a homozygous deletion of TP53 and CDKN2A, resulting in p53 and p16 deficiency, while retaining wild-type KRAS. This genetic background provides a relevant platform for examining molecular mechanisms in NSCLC, particularly in the context of metastatic progression and altered tumor suppressor function. The p53-null status makes these cells an especially useful system for probing interactions between genomic instability, ciliary biology, and oncogenic signaling.
DYNC2H1 encodes the heavy chain subunit of the cytoplasmic dynein-2 motor complex, which is essential for retrograde intraflagellar transport (IFT) within primary cilia. This ATP-driven motor drives the movement of ciliary cargo along axonemal microtubules, a process critical for ciliogenesis and the maintenance of ciliary structure. DYNC2H1 function is regulated by transcription factors such as RFX3 and FOXJ1, and its activity is further influenced by Hedgehog morphogens, including SHH and IHH. Upon Hedgehog pathway activation, DYNC2H1-dependent retrograde transport modulates the processing and activity of GLI transcription factors (GLI1, GLI2, GLI3), which then regulate the expression of downstream targets like PTCH1, HHIP, and CCND1. Disruption of DYNC2H1 thus impairs ciliary assembly and blocks proper Hedgehog signal transduction by preventing the retrograde movement of signaling components.
In the NCI-H1299 background, DYNC2H1 knockout provides a unique opportunity to dissect the intersection between ciliary dysfunction and lung cancer biology. Given the p53-deficient, metastatic origin of these cells, the loss of dynein-2 function may reveal cilia-dependent contributions to processes such as proliferation, migration, and drug resistance. Hedgehog signaling is increasingly implicated in NSCLC stemness and chemoresistance; abrogation of this pathway through DYNC2H1 disruption may alter tumorigenic traits. This model thus allows researchers to evaluate whether retrograde IFT and primary cilia play a role in maintaining the malignant phenotype of lung adenocarcinoma cells with compromised tumor suppressor pathways.
This product is well suited for a wide range of experimental approaches. Common applications include immunofluorescence staining of primary cilia to assess ciliogenesis defects, Western blotting for Hedgehog pathway activation markers (e.g., GLI1, PTCH1), and RT-qPCR profiling of ciliary gene expression. Functional studies may involve migration and invasion assays, drug sensitivity testing with SMO inhibitors such as vismodegib, and co-immunoprecipitation to examine dynein-2 complex integrity. RNA-seq can further elucidate global transcriptomic changes upon DYNC2H1 loss. These polyclonal knockout cells serve as a robust resource for probing ciliary roles in lung cancer, validating Hedgehog pathway dependency, and advancing drug target discovery in ciliopathies. For further information, please contact Ascent Research.
